<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142700</url>
  </required_header>
  <id_info>
    <org_study_id>AI451-004</org_study_id>
    <secondary_id>2010-018702-36</secondary_id>
    <nct_id>NCT01142700</nct_id>
  </id_info>
  <brief_title>A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I</brief_title>
  <official_title>A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is
      safe, well tolerated, and has sufficient antiviral activity to progress to late stage
      clinical trials when combined with pegIFNα/RBV for treatment of chronically infected
      hepatitis C virus genotype 1 treatment-naive subjects.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the frequency of serious adverse events (SAEs) and discontinuations due to adverse events (AEs)</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity as determined by the proportion of subjects with extended rapid virologic response (eRVR) defined as undetectable HCV RNA</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity as determined by the proportion of subjects with extended rapid virologic response (eRVR) defined as undetectable HCV RNA</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with rapid virologic response (RVR), defined as undetectable RNA</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with complete early virologic response (cEVR), defined as undetectable HCV RNA</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a sustained virologic response (SVR), defined as HCV RNA undetectable</measure>
    <time_frame>Week 12 (SVR12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a sustained virologic response (SVR), defined as HCV RNA undetectable</measure>
    <time_frame>Week 24 (SVR24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistant variants associated with virologic failure</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistant variants associated with virologic failure</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistant variants associated with virologic failure</measure>
    <time_frame>Follow up Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistant variants associated with virologic failure</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Hepatitis C Virus Genotype 1</condition>
  <arm_group>
    <arm_group_label>BMS-824393 (10mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plus Peginterferon Alfa-2a and Ribavirin
Day 1 - Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-824393 (30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plus Peginterferon Alfa-2a and Ribavirin
Day 1 - Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-824393 (100 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Plus Peginterferon Alfa-2a and Ribavirin
Day 1 - Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Plus Peginterferon Alfa-2a and Ribavirin
Day 1 - Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peginterferon alfa-2a plus Ribavirin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Weeks 13 - 48</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-824393</intervention_name>
    <description>Capsule, Oral, 10 mg, once daily</description>
    <arm_group_label>BMS-824393 (10mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-824393</intervention_name>
    <description>Capsule, Oral, 30 mg, once daily</description>
    <arm_group_label>BMS-824393 (30 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-824393</intervention_name>
    <description>Capsule, Oral, 100 mg, once daily</description>
    <arm_group_label>BMS-824393 (100 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule, Oral, 0 mg, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon Alpha-2a</intervention_name>
    <description>Syringe, subcutaneous 180 mcg/0.5 mL, weekly</description>
    <arm_group_label>BMS-824393 (10mg)</arm_group_label>
    <arm_group_label>BMS-824393 (30 mg)</arm_group_label>
    <arm_group_label>BMS-824393 (100 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Peginterferon alfa-2a plus Ribavirin</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily</description>
    <arm_group_label>BMS-824393 (10mg)</arm_group_label>
    <arm_group_label>BMS-824393 (30 mg)</arm_group_label>
    <arm_group_label>BMS-824393 (100 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Peginterferon alfa-2a plus Ribavirin</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment-naive subjects with genotype 1 chronic HCV

          -  HCV RNA ≥ 100,000 IU/mL at screening

          -  Seronegative for HIV and HBsAg

          -  Liver biopsy within prior 2 years demonstrating no cirrhosis

        Exclusion Criteria:

          -  Any evidence of liver disease other than hepatitis C

          -  Diagnosed or suspected hepatocellular carcinoma

          -  Laboratory values: neutrophil count &lt; 1500 cells/μL, platelet count &lt; 90,000/μL;
             Hemoglobin ≤ 12 g/dL (120g/L) for women and ≤ 13 g/dL (130 g/L) for men

          -  Cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research And Education, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bach And Godofsky Infectious Diseases</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Medical Center &amp; Research Solutions, Inc.</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists Of Georgia Pc</name>
      <address>
        <city>Mareitta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Digestive Disease Research</name>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute Of Virginia Bon Secours Health System</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>March 14, 2011</last_update_submitted>
  <last_update_submitted_qc>March 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

